10:35am ET
Health and Healthcare
Merck Prepares to Break Into HCV Market With Recent Study Results
Merck is joining the likes of Gilead Sciences in producing hepatitis C vaccines, but it is still in the early clinical stages.
Companies
/Healthcare
Gilead Sciences Inc
$148.09
▼ $0.68 (−0.46%) today
Markets closed · 12:40am ET
GILD Coverage
Page 317:45am ET
Health and Healthcare
Short Sellers Run for Cover From Major Biotechs
The short interest data are out for the October 30 settlement date, and short interest fell in selected biotech stocks.
9:10am ET
Health and Healthcare
4 Key FDA Decisions Expected in November and December
24/7 Wall St. has collected several big FDA decisions coming up in the month of November.
4:22pm ET
Health and Healthcare
Are Gilead Earnings Enough for Investors?
Gilead Sciences reported its third-quarter financial results after the markets closed on Tuesday.
Chris Lange 12:55pm ET
Health and Healthcare
What to Look For in Gilead Earnings
Gilead Sciences is set to report its third-quarter financial results after the markets close on Thursday.
8:10am ET
Health and Healthcare
Short Sellers Become More Selective on Leading Biotechs
The October 15 short interest data have been compared with the previous figures, and short interest mixed in these selected biotech stocks.
9:40am ET
Health and Healthcare
8 BioPharma Movers That Cannot Be Ignored
These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the course of the past week.
4:31pm ET
Health and Healthcare
How FDA Warning Could Spell Disaster for AbbVie and Opportunity for Gilead
ThinkstockThe U.S. Food and Drug Administration (FDA) issued a warning that hepatitis C treatments, Viekira Pak and Technivie, can cause serious liver injury mostly in patients with underlying advanced liver disease. The…
10:05am ET
Health and Healthcare
Q3 Worst for Biotech in 7 Years: Which Large Cap Leaders to Buy Now
Cowen says the way to play biotech is with large cap sector leaders that can beat earnings estimates. It also thinks third-quarter earnings beats could highlight the risk of not owning biotech…
8:55am ET
Investing
Top Analyst Upgrades and Downgrades: Bluebird Bio, Boston Beer, Etsy, Gilead, Pfizer, PMC-Sierra, Valeant and More
Tuesday's top analyst upgrades, downgrades and initiations include Bluebird Bio, Boston Beer, Etsy, Gilead Sciences, Pfizer, PMC-Sierra and Valeant Pharmaceuticals.
8:20am ET
Health and Healthcare
Short Sellers Increase Bets in Major Biotechs
The September 30 short interest data have been compared with the previous figures, and short interest increased in most of these selected biotech stocks for this settlement date.
10:05am ET
Health and Healthcare
UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
10:25am ET
Investing
UBS Makes Big Biotech and Pharmaceutical Additions to Equity Focus List
Wikimedia CommonsIf there was ever a time when investors are thrilled to see the calendar change it could be now. With the fourth quarter just starting, many are more than relieved to…
8:45am ET
Investing
Top Analyst Upgrades and Downgrades: AIG, Facebook, Gilead, Google, Regeneron, Twitter, Valeant, Vertex and More
Friday’s top analyst upgrades, downgrades and initiations include AIG, Facebook, Gilead Sciences, Google, Regeneron Pharmaceuticals, Twitter, Valeant Pharmaceuticals and Vertex Pharmaceuticals.
9:25am ET
Health and Healthcare
How the Top Biotechs Handled the Valuation Shock
24/7 Wall St. has taken a look at some of the largest biotech companies and highlighted the damage that a single tweet did to them last week.